PEG-Asparaginase is a PEGylated form of L-Asparaginase
- PEGylation increases enzyme half-life
- Lower allergic reactions compared to native L-Asparaginase
- Manufactured under stringent GMP conditions to ensure consistent potency
Product application
- • Clinical and preclinical studies in oncology
- • Research and development in biopharmaceuticals
- • Pharmaceutical formulations for acute lymphoblastic leukemia (ALL) treatment
PEG-Asparaginase is a PEGylated form of L-Asparaginase, an enzyme widely used in the treatment of acute lymphoblastic leukemia (ALL). The PEGylation enhances stability, prolongs half-life, and reduces immunogenicity, making it a preferred choice for therapeutic applications.
Why Choose Us?
- Lorven Biologics Private Limited specializes in the development and large-scale production of high-quality therapeutic enzymes. With a strong commitment to innovation and compliance, we ensure reliable and cost-effective bulk supply solutions for global partners.
Key features & Benefits
- Enhanced Stability: PEGylation increases enzyme half-life and reduces degradation.
- Reduced Immunogenicity: Lower allergic reactions compared to native L-Asparaginase.
- High Purity & Activity: Manufactured under stringent GMP conditions to ensure consistent potency.
- Extended Circulation Time: Allows for reduced dosing frequency in therapeutic applications.
- Reliable Bulk Supply: Scalable production to meet global pharmaceutical and biopharma needs.
Specifications
- • PEGylation: Site-specific PEG modification
- • Specific Activity: ≥ 85 IU/mg
- • Endotoxin Level: ≤ 50 EU/mL
- • Storage: 2–8°C or -20°C for long-term stability
Compliance & Quality Assurance
- • Manufactured in cGMP-compliant facilities
- • Stringent quality control and batch-to-batch consistency
- • Regulatory support available for global market approvals
Our trusted partners
